Rick, you should have been a fortune teller. You hit the nail on the head last March when you said in a misc. stock newsgroup:
"C.A. Pinkert (pinkert@cmed.bhs.uab.edu) wrote:
: In 1994, the stock was trading for $8-10 per share. It has since been
: downhill except for a June-October 1995 bounce back to $4-6 per share (in May
: 95 it was as low as 2 3/4, with a high of $6 in Sept. 95).
NTII is clearly a turn-around play, based on the recent addition of
memantine. While I don't write off Dynorphin A, CRF clearly looks, to
me, like baggage. :-)
However, the entire pharma industry is after an effective NMDA receptor antagonist, and I am of the opinion that memantine may be it. As I indicated in my previous post (?), NTII also has rights to work from Lipton's lab with respect to antagonists that bind at the redox modulatory site. This includes, I believe, rights to a patent claim involving high dose nitroglycerine for stroke.
So....... I regard the poor price performance of NTII as a blessing.
The question is, do you want to get in before or after everyone
recognizes value? The performance to date was based on results with CRF."
_____
That sage opinion is even more relevant today. I see the release again, of bad news on CFR, to be a buying opportunity for anyone who believes that Memantine has a reasonable chance of success. This old hippie bought more today.
Peace,
Bob Cohen |
